Medical/Pharmaceuticals
Bridge Biotherapeutics Announces China NMPA Clearance of IND for BBT-401, a Pellino-1 Inhibitor for UC
* China NMPA cleared the IND application of BBT-401 submitted on September 25, 2019 * The Phase I clinical study in China will be initiated in May 2020 SEONGNAM, South Korea, Dec. 26, 2019 /PRNewswire/ -- Bridge Biotherapeutics Inc. (KOSDAQ: 288330), a clinical stage biotech company headquart...
2019-12-27 06:30
1758
GenScript and Selecxine Enter Into Strategic Cooperation Agreement
SEOUL, South Korea, Dec. 26, 2019 /PRNewswire/ -- On Dec. 23, 2019, at Seoul, South Korea, the CDMO segment of the world's leading biotech company GenScript announced that it signed a strategic collaboration agreement with Selecxine Inc., a Korean biotech company dedicated to novel therapeutics f...
2019-12-26 22:00
10992
Viva Biotech Awarded 'Top 10 Public Companies'
BEIJING, Dec. 24, 2019 /PRNewswire/ -- The 'Future Healthcare VB 100 Summit' organized by VCBeat and VCBeat Research was held inBeijing. Viva Biotech was invited to the Summit and awarded the 'Top 10 Public Companies 2019' with honor. Dr. David Xu, the Chief Business Officer of Viva Biotech, was ...
2019-12-24 18:18
1484
Saluda Medical Results of U.S. Evoke Pivotal Study through 12 Months Published in The Lancet Neurology
Demonstrates Evoke® ECAP-Controlled Closed-Loop SCS Provides Statistically Superior Pain Relief Compared to Open-Loop SCS ARTARMON, Australia, Dec. 20, 2019 /PRNewswire/ -- Saluda Medical Pty Limited ("Saluda Medical") today announcedThe Lancet Neurology journal published results from the U.S. P...
2019-12-21 07:48
1737
HISKY, a leader in the innovative detection technology of liver health, launches the new brand iLivTouch
BEIJING, Dec. 20, 2019 /PRNewswire/ -- Recently, Wuxi Hisky Medical Technologies Co., Ltd. (hereinafter referred to as "HISKY") has successfully launched its new brand iLivTouch based on the MigTE technology. "On the increasingly competitive market, cycles of technological innovation are key to ...
2019-12-20 15:49
986
Bridge Biotherapeutics Files Investigational New Drug Application for BBT-176, an EGFR TKI for NSCLC
SEONGNAM, South Korea, Dec. 19, 2019 /PRNewswire/ -- Bridge Biotherapeutics Inc., a clinical stage biotech company headquartered in Seongnam, South Korea, announced that the company filed an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) and the Ministry...
2019-12-20 10:19
1283
Specialised Therapeutics Signs Exclusive Deal for New Haematology Drug
SINGAPORE, Dec. 18, 2019 /PRNewswire/ -- Independent pharmaceutical company Specialised Therapeutics Asia (STA) has signed an exclusive license deal with US-based Onconova Therapeutics (NASDAQ: ONTX), securing commercialisation rights to a new therapy for the treatment of Myelodysplastic Syndrome...
2019-12-18 22:00
2783
Dr. Jie Jack Li joins Shanghai ChemPartner as a Vice President of Discovery Chemistry
SHANGHAI, Dec. 17, 2019 /PRNewswire/ -- Shanghai ChemPartner announced the appointment ofJie Jack Li, Ph.D. as a Vice President of Discovery Chemistry at the Company headquarters inShanghai, China. Dr. Li is an established chemist with over 20 years of experience in both medicinal chemistry and ...
2019-12-18 00:00
1970
TransThera Biosciences Announces IND Approval from FDA for Clinical Studies of TT-00920 to Treat Chronic Heart Failure
NANJING, China, Dec. 16, 2019 /PRNewswire/ -- TransThera Biosciences Co. Ltd, a clinical-stage biotechnology company based inNanjing, China, announced today that the U.S. Food and Drug Administration (FDA) has granted the company's Investigational New Drug (IND) application for TT-00920, a novel ...
2019-12-17 08:00
1452
Senhwa Biosciences Reports Positive Phase 1 Data of CX-5461 in Patients With Advanced Solid Tumors at 2019 SABCS
TAIPEI and SAN DIEGO, Dec. 12, 2019 /PRNewswire/ -- Senhwa Biosciences Inc. (TPEx: 6492), a clinical stage biopharmaceutical company focused on next generation DNA Damage Response (DDR) therapeutics for the treatment of cancer, today announced positive results from its Phase 1 trial of CX-5461. C...
2019-12-13 04:00
2409
United Imaging's Artificial Intelligence Subsidiary Wins in Facebook AI Research & NYU School of Medicine Global Competition
HOUSTON, Dec. 12, 2019 /PRNewswire/ -- United Imaging, a global leader in advanced medical imaging and radiotherapy equipment, followed a strong appearance at the annual meeting of the Radiological Society ofNorth America (RSNA) with a win in a competition jointly organized by Facebook AI Researc...
2019-12-12 21:00
1670
iX Biopharma Reports on Outcome of Wafermine End-of-phase 2 Meeting with US FDA
SINGAPORE, Dec. 11, 2019 /PRNewswire/ -- Specialty pharmaceutical company iX Biopharma Ltd(SGX:42C) ("iX Biopharma" or, "the Company") is pleased to announce that it has successfully concluded an End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) regarding Wafermine, a sublin...
2019-12-11 22:00
1949
Breakthrough in Medical Electronics - A Novel Mixed & Augmented Reality Smart Glasses Surgical Navigation Solution
TAICHUNG, Dec. 10, 2019 /PRNewswire/ -- The mixed reality technology for surgery usually shown in the movies has now become a reality with the latest technological offering from theTaiwan-based company – Taiwan Main Orthopaedics Biotechnology and the branding name of medical devices is SURGLAS...
2019-12-10 16:34
920
Gracell Announces Progressive Outcomes from Multiple Human Clinical Trials to Investigate FasTCAR and Dual CAR Cell Platform Technologies
SUZHOU, China and SHANGHAI, Dec. 9, 2019 /PRNewswire/ -- Gracell Biotechnologies Co., Ltd ("Gracell"), a clinical-stage immune cell therapy company, today announced the progressive clinical outcomes for leading product candidates FasTCAR-19, Dual CAR-19-22, and Dual CAR-BCMA-19 at the American...
2019-12-09 22:00
1391
BJ Bioscience Announces First Patient Dosed in FIH Trial of BJ-001 in Patients with Locally Advanced/Metastatic Solid Tumors
HANGZHOU, China, Dec. 9, 2019 /PRNewswire/ -- BJ Bioscience Inc. (the
'company') today announced that the first patient was successfully dosed on
December 4, 2019 in the first-in-human (FIH) trial of the company's BJ-001
program at NEXT ONCOLOGY inSan Antonio, Texas.
2019-12-09 21:00
1550
CARsgen Therapeutics Receives IND Clearance from the NMPA for AB011 Humanized Claudin18.2 Monoclonal Antibody
SHANGHAI, Dec. 9, 2019 /PRNewswire/ -- CARsgen Therapeutics, a clinical-stage biopharmaceutical company committed to discovering and developing a combined platform of Chimeric Antigen Receptor T (CAR-T) cell therapies and monoclonal antibodies for cancer, today announced that one of its leading d...
2019-12-09 18:00
3359
Korean ophthalmologist Oh Jungwoo performed '25 sec LASEK' in public for the first time
SEOUL, South Korea, Dec. 6, 2019 /PRNewswire/ -- Dr. Oh Jungwoo from Eos Eye Center in Gangnam-gu, Korea, revealed '25 sec LASEK' surgery publicly by video. This is the first time the operation has been released to the public and it shows Dr. Oh's surgery on a patient's left eye with minimal corn...
2019-12-06 22:00
1341
Ping An Good Doctor and Merck KGaA, Darmstadt, Germany Form Strategic Collaboration to Advance Intelligent Healthcare in China
SHANGHAI, Dec. 4, 2019 /PRNewswire/ -- Ping An Healthcare and Technology Company Limited (Stock code: "Ping An Good Doctor", 1833.HK) one of the world's leading healthcare ecosystem platforms, signed a strategic collaboration agreement today with Merck KGaA, Darmstadt,Germany, a leading science a...
2019-12-04 16:01
5943
United Imaging, BAMF Health Bring Bold Vision to Life: Global Strategic Partnership Advances Theranostics and Precision Medicine
HOUSTON, Dec. 3, 2019 /PRNewswire/ -- United Imaging, a global leader in advanced medical imaging and radiotherapy equipment, announced today a global, strategic partnership with BAMF Health, an organization that is achieving AI-enabled precision medicine through molecular imaging and theranostic...
2019-12-03 21:00
1063
Lumosa Announces FDA Acceptance of IND Application for LT1001, an Extended-Release Analgesic Injection - Lumosa to Initiate the Bridging Study in the US
TAIPEI, Dec. 3, 2019 /PRNewswire/ -- Opioid misuse, addiction, and overdoses have caused significant social and economic burdens leading to the opioid crisis. LT1001 (brand name Naldebain®) is a prodrug of nalbuphine, an abuse-free analgesic that has been marketed worldwide for decades. Naldebain...
2019-12-03 17:36
1116
Week's Top Stories
Most Reposted
Rockwell Automation and Microsoft Deliver on a Shared Vision to Accelerate Industrial Transformation
[Picked up by 305 media titles]
2024-11-20 13:29Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
[Picked up by 299 media titles]
2024-11-20 16:30
Travel loyalty programs to focus on offering personalized and flexible customer experiences in 2025
[Picked up by 298 media titles]
2024-11-19 10:42Oxygen, HubSpot's leading solutions partner in Hong Kong & Greater China Expands to UAE
[Picked up by 296 media titles]
2024-11-15 15:25
Philips and Edith Cowan University Australia Collaborate to Equip the Next Generation of Healthcare Professionals to leverage new technologies
[Picked up by 283 media titles]
2024-11-20 09:00
Most Read
Oxygen, HubSpot's leading solutions partner in Hong Kong & Greater China Expands to UAE
2024-11-15 15:25
8674
How "small apples" march into "big industry" in Yan'an
2024-11-15 17:39
5354
Yingli Solar's Global Product Workshops Launched in Malaysia
2024-11-15 21:40
4730
Strategic Forum in Chongqing Drives Expansion of New Western Land-Sea Corridor
2024-11-16 14:15
4681